このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Gan & Lee Pharmaceuticals マネジメント

マネジメント基準チェック /44

Gan & Lee Pharmaceuticals'の CEO はKai Duで、 Jul2020年に任命され、の在任期間は 4.08年です。は、会社の株式の0.087%を直接所有しており、その価値はCN¥ 22.32M 。経営陣と取締役会の平均在任期間はそれぞれ4.1年と4.4年です。

主要情報

Kai Du

最高経営責任者

CN¥1.0m

報酬総額

CEO給与比率	n/a
CEO在任期間	4.3yrs
CEOの所有権	0.09%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Sep 04

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Apr 29

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Mar 01

CEO（最高経営責任者

Kai Du (47 yo)

4.3yrs

在職期間

CN¥1,041,900

報酬

Mr. Kai Du is General Manager of Gan & Lee Pharmaceuticals. since July 20, 2020 and has been its Director since April 26, 2019.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 10.3b
Kai Du	GM & Director	4.3yrs	CN¥1.04m	0.087% CN¥ 25.4m
Cheng Sun	CFO & Deputy GM	4.3yrs	CN¥695.20k	0.022% CN¥ 6.4m
Wei Chen	Deputy GM & Director	less than a year	CN¥892.20k	0.087% CN¥ 25.4m
Weiqiang Song	Deputy GM & Director	8.8yrs	CN¥960.50k	0.087% CN¥ 25.4m
Rong Zou	Secretary	6.8yrs	CN¥695.00k	0.087% CN¥ 25.4m
Cheng Xing	Deputy General Manager	4.3yrs	CN¥752.80k	0.087% CN¥ 25.4m
Zifei Yuan	Deputy General Manager	4.3yrs	CN¥710.50k	0.087% CN¥ 25.4m
Zhi Li	Deputy General Manager	less than a year	データなし	データなし

4.3yrs

平均在職期間

42yo

平均年齢

経験豊富な経営陣: 603087の経営陣は経験豊富であると考えられます ( 4.1年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Gan Zhongru	Founder & Chairman	26.8yrs	CN¥457.20k	35.48% CN¥ 10.3b
Kai Du	GM & Director	5.5yrs	CN¥1.04m	0.087% CN¥ 25.4m
Wei Chen	Deputy GM & Director	3.1yrs	CN¥892.20k	0.087% CN¥ 25.4m
Weiqiang Song	Deputy GM & Director	9.1yrs	CN¥960.50k	0.087% CN¥ 25.4m
Jiao Jiao	Director	3.6yrs	CN¥1.04m	0.045% CN¥ 13.2m
Lei Yin	Director	3.6yrs	CN¥897.10k	0.020% CN¥ 5.9m
Yanqing He	Independent Director	5.5yrs	CN¥72.00k	データなし
Guojun Zheng	Independent Director	5.5yrs	CN¥72.00k	データなし
Yi Wang	Supervisor	3.6yrs	データなし	データなし
Tao Zhang	Chairman of the Board of Supervisors	3.1yrs	データなし	データなし
Jiaxin Wang	Supervisor	5.5yrs	データなし	データなし
Zengyi Chang	Independent Director	2.4yrs	CN¥72.00k	データなし

4.5yrs

平均在職期間

44.5yo

平均年齢

経験豊富なボード: 603087の取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

Gan & Lee Pharmaceuticals マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

Less than half of directors are independent

Recent updates

Gan & Lee Pharmaceuticals. to Report Q3, 2024 Results on Oct 23, 2024

Investor sentiment improves as stock rises 18%

Gan & Lee Pharmaceuticals. (SHSE:603087) announces an Equity Buyback for CNY 300 million worth of its shares.

Shareholders In Gan & Lee Pharmaceuticals (SHSE:603087) Should Look Beyond Earnings For The Full Story

Second quarter 2024 earnings: EPS in line with expectations, revenues disappoint

Gan & Lee Pharmaceuticals. to Report First Half, 2024 Results on Aug 29, 2024

Price target increased by 7.8% to CN¥62.50

Analysts Just Shipped A Sizeable Upgrade To Their Gan & Lee Pharmaceuticals. (SHSE:603087) Estimates

Gan & Lee Pharmaceuticals., Annual General Meeting, May 16, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Gan & Lee Pharmaceuticals. to Report Q1, 2024 Results on Apr 25, 2024

Some Confidence Is Lacking In Gan & Lee Pharmaceuticals.'s (SHSE:603087) P/S

Gan & Lee Pharmaceuticals. to Report Fiscal Year 2023 Results on Apr 25, 2024

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.39 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.55 loss in 2Q 2022)

First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.20 in 1Q 2022)

Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index (USD)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.39 loss per share (vs CN¥0.90 profit in 3Q 2021)

Gan & Lee Pharmaceuticals. announced that it expects to receive CNY 813.6 million in funding

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.55 loss per share (vs CN¥0.32 profit in 2Q 2021)

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Third quarter 2021 earnings released: EPS CN¥0.90 (vs CN¥0.70 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.32 (vs CN¥0.34 in 2Q 2020)

Investor sentiment deteriorated over the past week

Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results at the 81st Scientific Sessions of the American Diabetes Association

First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.24 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥2.31 (vs CN¥2.31 in FY 2019)

New 90-day low: CN¥121

FDA Grants Fast Track Designation for Gan & Lee Pharmaceuticals Co., Ltd.'s GLR2007, for the Treatment of Patients with Glioblastoma

Investor sentiment improved over the past week

New 90-day high: CN¥174

Investor sentiment improved over the past week

New 90-day high: CN¥136

New 90-day low: CN¥115

Third quarter earnings released

Earnings released

Gan & Lee Pharmaceutical, Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Gan & Lee Pharmaceutical, Ltd. announced that it has received funding from Hillhouse Capital Management, Ltd.

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44